Newsroom

WHIPPANY, N.J.--(BUSINESS WIRE)--ASCO 2026: Bayer Shares New Findings for NUBEQA for Cognitive Decline in Men with aPC Compared to Enzalutamide in Phase II ARACOG Head-to-Head Trial...

WILMINGTON, Del.--(BUSINESS WIRE)--  Cruciale frontMIND-studie van Incyte heeft aangetoond dat de combinatie van tafasitamab (Monjuvi®/Minjuvi®) de progressievrije overleving significant verlengde en het risico op ziekteprogressie of overlijden met 25% verlaagde bij patiënten met eerder onbehandeld, hoogrisico DLBCL. Incyte (Nasdaq: INCY) heeft vandaag positieve resultaten bekendgemaakt van de cruciale Fase 3 frontMIND-studie, waarin de werkzaamheid en veiligheid werd beoordeeld van tafasitamab...

WILMINGTON, Delaware--(BUSINESS WIRE)--Incyte's frontMIND trial found Tafasitamab (Monjuvi/Minjuvi) combo significantly prolongs progression-free survival in high-risk DLBCL patients...

WILMINGTON, Delaware--(BUSINESS WIRE)--  El ensayo fundamental frontMIND de Incyte demostró que la combinación con tafasitamab (Monjuvi®/Minjuvi®) prolongó significativamente la supervivencia libre de progresión, lo que reduce en un 25 % el riesgo de progresión de la enfermedad o muerte en pacientes con linfoma difuso de células B grandes de alto riesgo no tratado previamente Incyte (Nasdaq:INCY) anunció hoy resultados positivos del ensayo fundamental frontMIND fase 3, que evalúa la eficacia y...

WILMINGTON, Delaware--(BUSINESS WIRE)--  frontMIND, lo studio clinico cardine di Incyte ha dimostrato come la combinazione tafasitamab (Monjuvi®/Minjuvi®) sia in grado di prolungare notevolmente la sopravvivenza libera da progressione, riducendo il rischio di progressione della malattia o di decesso del 25% in pazienti affetti da DLBCL ad alto rischio precedentemente non trattato Incyte (Nasdaq:INCY) ha annunciato oggi i risultati positivi ottenuti dallo studio clinico cardine di Fase 3 frontMI...

GAITHERSBURG, Md.--(BUSINESS WIRE)--Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, today announced updated data from the Phase 1/2 study of JK06, a 5T4-targeted antibody drug conjugate (ADC), in patients with unresectable locally advanced or metastatic solid tumors, including non-small cell lung cancer (NSCLC) and breast cancer. The data are being presented at the 2026 American Soc...

SINGAPORE--(BUSINESS WIRE)--BW LPG Limited (“BW LPG”, the “Company”, OSE ticker code: “BWLPG.OL”), the world’s leading owner and operator of LPG vessels, announces that it has signed a contract for the construction of eight 90’cbm Panamax Very Large Gas Carriers (VLGCs), for a total consideration of about US$940 million, subject to the final technical specifications. The newbuildings are expected to be delivered sequentially from the start of 2029 until the second quarter of 2030. “This newbuil...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026...

SAN DIEGO--(BUSINESS WIRE)--The case alleges Sportradar and certain of its top executives made false and/or misleading statements to investors....

SAN DIEGO--(BUSINESS WIRE)--The case alleges Commvault and certain of Commvault’s executive officers made false and/or misleading statements to investors....